Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | LIPE | Q05469 | 2/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL707043 | 1.00 | GPR119 (0.46) | GPR119USP30JAK2JAK1NR1H2 | |
| SCHEMBL10038438 | 1.00 | GPR119 (0.46) | GPR119USP30JAK2JAK1NR1H2 | |
| SCHEMBL13461072 | 0.86 | GPR119 (0.50) | GPR119USP30JAK2JAK1NR1H2 | |
| SCHEMBL13433734 | 0.86 | GPR119 (0.50) | GPR119USP30JAK2JAK1NR1H2 | |
| SCHEMBL3177397 | 0.86 | GPR119 (0.50) | GPR119USP30JAK2JAK1NR1H2 | |
| SCHEMBL705741 | 0.84 | HDAC4 (0.39) | — | |
| SCHEMBL5522852 | 0.80 | HDAC1 (0.48) | GPR119USP30NR1H2LIPERORC | |
| SCHEMBL5520664 | 0.80 | HDAC1 (0.48) | GPR119USP30NR1H2LIPERORC | |
| SCHEMBL22398001 | 0.79 | NR1H2 (0.53) | GPR119USP30NR1H2 | |
| SCHEMBL2114177 | 0.79 | NR1H2 (0.53) | GPR119USP30NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2144503-B9 | 4-(octahydro-2H-isoindol-2-yl)-1,3-oxazol-4-one as TACHYKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-09-04 | — | — | EP | disclosed |
| EP-2144503-B1 | 4-(octahydro-2H-isoindol-2-yl)-1,3-oxazol-4-one as TACHYKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-03-27 | — | — | EP | disclosed |
| US-8124633-B2 | Hydroxymethyl ether hydroisoindoline tachykinin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100197724-A1 | 6.5 -PYRROLOPIPERIDINE TACHYKININ RECEPTOR ANTAGONISTS | BAO JIANMING | 2010-08-05 | — | — | US | disclosed |
| US-20100105747-A1 | HYDROXYMETHYL ETHER HYDROISOINDOLINE TACHYKININ RECEPTOR ANTAGONISTS | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2010-04-29 | — | — | US | disclosed |
| WO-2008124143-A1 | HYDROXYMETHYL ETHER HYDROISOINDOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105747-A1 | HYDROXYMETHYL ETHER HYDROISOINDOLINE TACHYKININ RECEPTOR ANTAGONISTS | TACR1, HTR1D, TACR2 | GPR119 762/4885USP30 4119/4885JAK2 1677/4885 |
| US-20100197724-A1 | 6.5 -PYRROLOPIPERIDINE TACHYKININ RECEPTOR ANTAGONISTS | TACR1, TACR2, HTR1D | GPR119 910/4885USP30 3946/4885JAK2 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.